Latest Regulatory Milestones News

Magnetite Mines Limited has made significant strides in advancing its Razorback Iron Ore Project, securing a $7 million funding facility and progressing strategic partnerships with JFE Shoji Australia. The company is also preparing to submit its Mining Lease Proposal to the South Australian Government amid a streamlined board and cost-cutting measures.

Patronus Resources reports significant drilling progress across its Western Australia and Northern Territory projects, with strong assay results at Mertondale and a robust cash position supporting ongoing exploration.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Sandfire Resources reported a 5% increase in copper equivalent production for H1 FY25, alongside a reduction in injury rates and operating costs at its Motheo operation. The company secured key approvals for a new tailings facility at MATSA, underpinning long-term growth.

E79 Gold Mines reports exceptional copper, gold, and bismuth assay results from its Mountain Home Project and gains Northern Territory government approval to commence drilling in 2025.

NeuRizer Ltd has resolved key regulatory delays for its NeuRizer Urea Project, significantly cut operating costs, and is forging international partnerships to expand its In Situ Gasification technology.

Quantum Graphite has lodged its final US$300 million financing application with the US EXIM Bank for Project Utile, alongside securing a new exploration license EL7019 in South Australia. The company is poised to release updated JORC 2012 exploration targets soon, underpinning its growth strategy.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.